Published: June 2024

Last updated: June 2024

Single-Arm Studies in Literature Reviews: Trials Versus Case Series

INTRODUCTION: Single-arm studies, particularly single-arm trials (SATs), are increasingly being used in submissions for marketing authorization and health technology assessment. As reviewers of evidence, we sought to better understand the validity of SATs, compared with observational single-arm studies (case series), and how to assess them in our reviews.

METHODS: We conducted a highly pragmatic literature review to create a convenience sample of recent systematic reviews published from January to July 2023 to establish the following: (i) what single-arm study designs are included; (ii) what quality assessment tools are used; and (iii) whether there is a difference in effect size and variability among different study designs. A single reviewer identified reviews of interventions that included single-arm studies and extracted information on the numbers of included SATs and case series, and the quality assessment tools used. Any misclassifications by review authors were identified. For meta-analyses, outcome data were extracted and a subgroup analysis comparing SATs and case series was conducted.

RESULTS: Work is still underway to complete this investigation. So far, it appears that a large proportion of systematic reviews misclassify SATs and case series studies and few use appropriate quality assessment tools. There is not yet any evidence of a systematic difference between SATs and case series in terms of effect size.

CONCLUSIONS: Findings suggest that there is poor understanding of SATs in the review community. There are limited specific quality assessment tools for SATs and review authors frequently use inappropriate tools to assess them. More research is likely to be needed to investigate the relative validity of SATs and single-arm observational studies.

You may also be interested in

Peer-reviewed publication

A Disease Progression Model Comparing the Long-Term Mobility and Respiratory Outcomes of Adults with Late-Onset Pompe Disease Receiving Cipaglucosidase Alfa Plus Miglustat versus Alglucosidase Alfa

YHEC authors: Amy Dymond, Will Green
Publication date: July 2026
Journal: Journal of Comparative Effectiveness Research

Abstract

AIM: Late-onset Pompe disease (LOPD) is a rare lysosomal disease primarily impacting muscle strength andrespiratory function. LOPD has a substantial burden despite the availability of alglucosidase alfa (alg). Patients often...

Peer-reviewed publication

Addressing Real-World Data Gaps: Estimating the UK Population Cost of Crohn’s Disease and Ulcerative Colitis Using A Flexible Cost-of-Illness Model Informed by the Optimal Patient Journey and IBDUK Patient Survey 2023

YHEC authors: Rachael MacDonald, Nick Hex, Barbara Uzdzinska, Jessica Pocock
Publication date: July 2026
Journal: BMC Health Services Research

Abstract

BACKGROUND: Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), are chronic conditions affecting around 500,000 people in the UK and carries rising prevalence and substantial economic...

Peer-reviewed publication

Next Generation Methods in Health Technology Assessment (HTA): Need, Rigor, and Implementability

YHEC authors: Melissa Pegg
Publication date: July 2026
Journal: International Journal of Technology Assessment in Healthcare

Abstract

The Health Technology Assessment International (HTAi) 2025 annual meeting featured three main plenaries to explore next generation (NextGen) evidence in health technology assessment (HTA). In this commentary we capture the...